Navigation Links
Oral PBI-1402 Demonstrates Significant Activity in Chemotherapy-Induced Anemia Phase II Clinical Trial
Date:4/23/2008

More than 90% of CIA patients treated with PBI-1402 did not require blood

transfusion.

MONTREAL, April 23 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") announces that oral PBI-1402 demonstrates significant activity in patients with chemotherapy-induced anemia ("CIA"), and reduces the need for red blood cell ("RBC") transfusion.

Only 2 patients out of 28 (7%) treated with PBI-1402 required a RBC transfusion, a response rate greater than 90% with regards to this clinical objective. In the March 13, 2008 FDA briefing document, the Oncologic Drugs Advisory Committee emphasizes that the primary objective of treating CIA patients with erythropoiesis-stimulating agents ("ESAs") as being the ability to reduce the need for RBC transfusion. The Advisory Committee cites that approximately 50% of anemic patients receiving chemotherapy required RBC transfusion, and 20%-25% of patients treated with ESAs still required RBC transfusions.

"These results are very exciting and meet the primary objective that formed the basis for FDA approval of other ESAs in CIA patients," states Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic Life Sciences Inc. "This new encouraging data further supports the potential role PBI-1402 could play in the management of anemia in patients with cancer," added Mr. Laurin.

CIA patients enrolled in the study received a once daily oral dose of PBI-1402 during a period of eight weeks while undergoing their normal course of chemotherapy. All patients enrolled have completed the PBI-1402 treatment period.

About PBI-1402

PBI-1402 is an orally active compound being developed to treat different types of anemia, such as CIA. PBI-1402 has a distinct mechanism of action and does not act through EPO receptor. ProMetic has recently expanded its clinical program for PBI-1402 into the treatment of anemia in patients with myelodysplastic syndrome
'/>"/>

SOURCE PROMETIC LIFE SCIENCES INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
2. ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study
3. Bringing a New Rhythm to Cardiology Workflow: Siemens Demonstrates Answers to Cardiologys Toughest Questions
4. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
5. USGI Medical Demonstrates First System for Gastrotomy Closure in NOTES
6. Job-related stress: NIST demonstrates fatigue effects in silicon
7. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
8. Magnifi Group Demonstrates Industrys First Interactive Educational Program (IEP) for Spine Fellows
9. ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients
10. Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder
11. Recent Study Confirms Alimentary Healths Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ... today reported financial results for the six months ... are expressed in Canadian dollars and presented under ... Quarter 2014 Highlights , Announced top-line ... (VA) primary endpoint for subjects enrolled in the ...
(Date:8/29/2014)... 2014 A major challenge before new ... dense realm of Boston-Cambridge, is gaining visibility that can ... Sherley, the Director of Boston’s Adult Stem Cell Technology ... national visibility of his company an important priority since ... addition to a social media marketing campaign ...
(Date:8/28/2014)... Ca. (PRWEB) August 28, 2014 Best ... rating for an alcohol-based hand sanitizer, asks food processors ... by comparing the hand sanitizer they’re currently using to ... . Hand hygiene is critical to fighting cross-contamination and ... Best Sanitizers believes there are key criteria that ...
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... new market research report is ... Whole Exome Sequencing Market ... Preparation, Target Enrichment), by Services ... Synthesis), by Application (Cancer, Monogenic ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13
... researchers at the Swedish medical university Karolinska Institutet shows ... "bad" LDL cholesterol and thereby cause an inflammation that ... T cell receptors, the researchers have managed to inhibit ... presented online in the distinguished periodical Journal of ...
... discovered that simple peptides can organize into bi-layer membranes. ... pre-biotic Earth,s chemical inventory and the organizational scaffolding essential ... form the kind of membranes needed to create long-range ... of the paper recently published by the German Chemical ...
... Conference Call on Thursday, May 6, 2010 at 4:30 p.m. Eastern Time , ... BOTHELL, WA , and VANCOUVER , May 6 /PRNewswire-FirstCall/ - OncoGenex ... three months ended March 31, 2010 and reviewed the Company,s highlights for the first quarter ... Financial Results , , , ...
Cached Biology Technology:New atherosclerosis vaccine gives promising results 2Peptides may hold 'missing link' to life 2Peptides may hold 'missing link' to life 3OncoGenex Reports First Quarter Financial Results 2OncoGenex Reports First Quarter Financial Results 3OncoGenex Reports First Quarter Financial Results 4OncoGenex Reports First Quarter Financial Results 5OncoGenex Reports First Quarter Financial Results 6OncoGenex Reports First Quarter Financial Results 7OncoGenex Reports First Quarter Financial Results 8OncoGenex Reports First Quarter Financial Results 9
(Date:8/28/2014)... PAUL (August 28, 2014) Researchers at the University ... facioscapulohumeral muscular dystrophy (FSHD) to be used for muscle ... of potential therapies for FSHD. , The research is ... Cell Reports . , There is no treatment for ... most common type of muscular dystrophy. FSHD is an ...
(Date:8/28/2014)... that could positively impact the global battle ... thanks to researchers in Penn State,s College ... made from the seaweed-derived food ingredient carrageenan ... provides a woman-initiated, drug-delivery vehicle that can ... infections during unprotected heterosexual intercourse, the researchers ...
(Date:8/28/2014)... 25 million kilometres of new roads will be built ... into Earth,s last wildernesses, where they bring an influx ... Now, an ambitious study has created a ,global roadmap, ... to balance the competing demands of development and environmental ... layer that estimates that natural importance of ecosystems and ...
Breaking Biology News(10 mins):UMN researchers find animal model for understudied type of muscular dystrophy 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3
... the European Medicines Agency (EMA) approved the modified adeno-associated ... for clinical use in the Western world. uniQure, a ... treatment of a rare inherited metabolic disease called lipoprotein ... out of one million people. The disease causes severe, ...
... 2013  Paris Air Show – Marvin Test Solutions ... provider of innovative test solutions for military and commercial ... the Paris Air Show in booth 3-C82. ... longer lifecycles, industry leaders are demanding efficient, feature-rich, specialized ...
... Kingdom, the Energy Department,s National Renewable Energy Laboratory (NREL), ... paper describing a novel cellulose-degrading enzyme from a marine ... the gribble. Gribbles are biologically intriguing because ... own enzymes instead of using symbiotic microbes to break ...
Cached Biology News:No danger of cancer through gene therapy virus 2Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 2Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 3Novel enzyme from tiny gribble could prove a boon for biofuels research 2
...
... Human IgG Fd. ELISA Specificity: (4) ,human IgG subclass 1 ... 100% ,human IgG subclass 3 100% ,human IgG ... ... 0.04% ,human IgG Fab ...
Human VEGF R2 (KDR) MAb (Clone 89106)...
Salmonella typhimurium Immunogen: Heat inactivated bacterial cells of Salmonella typhimurium B Storage: 4 C...
Biology Products: